DOC Updates

American Diabetes Association

DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles in the field of diabetes research and care, including the American Diabetes Association's three science and health journals – Diabetes, Diabetes Care, and Diabetes, Obesity, and Cardiometabolic CARE. Each episode is approximately 15 minutes long and presents 5-6 recently published articles from ADA journals and beyond.

Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research and information published in journals of the American Diabetes Association and beyond are relevant to clinical practice and can be applied in a treatment setting.

For more information about each of ADA's science and medical journals, please visit www.diabetesjournals.org.

Presented by:

Neil Skolnik, M.D. , Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, M.D., Clinical Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

Play

Open in

22 episodes
weekly
Avg 32 min
English

Episodes 22

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

Monday · 32 min
Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance
Weight maintenance is a challenging topic for both clinicians and patients. In this special episode, Neil Skolnik is joined by Jamie Almondoz, MD, who discusses the toxic narratives that have historically been part of the weight loss conversation, and the latest strategies for maintaining a healthy weight after the initial loss. This special episode is sponsored with support from Lilly. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jamie Almondoz, MD, Professor of Internal Medicine and the Medical Director of the Weight Wellness Program at the University of Texas Southwestern Medical Center and Vice-Chair of the American Board of Obesity Medicine (ABOM) References: Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. June 2026; 407:2305-2318 Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial. JAMA 2021;325;(14):1414-1425 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med 32, 2679–2687 (2026) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022; 24(8): 1553-1564
August 17 · 33 min
Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D
To achieve optimal outcomes for patients, it is not only the individual efforts of clinicians that matter in achieving optimal outcomes for our patients. Having a system that supports and facilitates those efforts is essential. In this special episode, Neil Skolnik speaks with Nihar Desai about the challenges of managing chronic kidney disease and diabetes. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Nihar Desai, MD, MPH, Associate Professor of Medicine and Associate Chief of the Section of Cardiovascular Medicine at Yale University School of Medicine, Investigator at the Center for Outcomes Research and Evaluation, and Medical Director for Value Innovation at the Yale New Haven Health System. Selected references: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1) :S246–S260 Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121
S1 · E6
August 10 · 35 min
Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!
With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. 1:15 Our hosts speak with Katherine R. Tuttle, MD, FASN, FACP, FNKF, Executive Director of Research at Providence Inland Northwest Health and a Professor of Medicine at the University of Washington School of Medicine. She is an author of the article "SGLT2 Inhibitors for the Primary Prevention of CKD in Type 2 Diabetes: A Systematic Review and Meta-analysis," available at doi.org/10.2337/doci26-0001. 8:50 Next, Richard introduces Alexander Turchin, MD, MS, Director of Informatics Research at the Division of Endocrinology at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School. He is an author of "Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022," available for free at doi.org/10.2337/doc26-0027. 17:05 Richard and Jane highlight special material available in the latest issue of Diabetes, Obesity, and CardioMetabolic CARE. "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity—2026," available for free at doi.org/10.2337/doci26-0003 "Employment and Diabetes: A Statement of the American Diabetes Association," available for free at doi.org/10.2337/doc25-0092. 23:40 Finally, Richard and Jane highlight some of their favorite articles from the July-August issue. Vidovic, et al. Behavior Modifications From CUT-DM, Including Lifestyle Modification and Self-Efficacy doi.org/10.2337/doc25-0093 Chan, et al. Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes doi.org/10.2337/doc26-0019 Bannuru, et al. RAAS Inhibitors for the Primary Prevention of CKD in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-analysis doi.org/10.2337/doci25-0014 Dimentstein, et al. Goals of Care Among Caregivers of Youths With Type 1 Diabetes doi.org/10.2337/doc26-0035 To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.
August 10 · 32 min
Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!
Welcome to the latest episode (August 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Hirsh Elhence, Jennifer L. Dodge, Stephen Fuest, et al. National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study. Ann Intern Med. [Epub 2 June 2026]. doi:10.7326/ANNALS-25-05287 Eva Johnsen, et al. Achieving at Least 15% Weight Loss Within 2 Years of Type 2 Diabetes Diagnosis Is Associated With Lower Risks of Macrovascular and Microvascular Complications: A U.K. Cohort Study. Diabetes Care 20 July 2026; 49 (8): 1480–1489. doi.org/10.2337/dc26-0937 Carel W. le Roux, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England Journal of Medicine June 2026 DOI: 10.1056/NEJMoa2600751 Yu Wang, Shichao Tang, Xilin Zhou, Ping Zhang. National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs Among U.S. Adults With Diabetes, 2000–2022. Diabetes Care 20 July 2026; 49 (8): 1414–1419. https://doi.org/10.2337/dc25-2040 Jelle M. Beernink, et al. Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial. Diabetes Care 20 July 2026; 49 (8): 1434–1441. https://doi.org/10.2337/dc26-0882 Welch M, Forst T, Jia W et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. The Lancet, 2026; 408, 125-140 DOI: 10.1016/S0140-6736(26)00800-7 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice. For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.
August 6 · 33 min
Special Edition: Hypertension Part I—Overview and Management
In the first episode of this special three-part series, Neil Skolnik speaks with Dr. Minesh Rajpal. Together, they provide an overview, discussing the assessment and management of high blood pressure. This special episode is sponsored with support from AstraZeneca. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Minesh Rajpal, MD, Attending Nephrologist and Hypertension Specialist at the Southwest Kidney Institute References: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee. Hypertension 2025; 82(10) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957
July 30 · 44 min
Special Edition: Highlights from the ADA's 2026 Scientific Sessions
In this special crossover episode, recorded live at the American Diabetes Association's Scientific Sessions in New Orleans, the hosts of the ADA's professional podcasts—DOC Updates, Diabetes Care "On Air", DiabetesBio, and The Points of CARE—come together to discuss key highlights and groundbreaking research presented at the 2026 meeting. They share expert insights across the bench-to-bedside spectrum, including basic science, clinical research, and the latest in diabetes care and education. Tune in for thoughtful reflections on what this year's findings mean for clinical practice and future research. Available now across all ADA professional podcast channels. Featured Podcasts: DOC Updates – ADA's podcast for primary care Diabetes Care "On Air" – From ADA's clinical research journal, Diabetes Care DiabetesBio – From ADA's flagship research journal, Diabetes The Points of CARE - The official podcast of Diabetes, Obesity, and CardioMetabolic CARE Join the Discussion with: Alice Cheng, MD – Co-host of Diabetes Care "On Air" Kirk Habegger, PhD – Co-host of DiabetesBio Michael Rickels, MD, MS – Co-host of Diabetes Care "On Air" Neil Skolnik, MD – Co-host of DOC Updates and Diabetes Day by Day Kevin Williams, PhD – Co-host of DiabetesBio Richard Beaser, MD – Co-host of The Points of CARE 🔗 Learn more about ADA's full podcast portfolio: https://diabetesjournals.org/journals/pages/podcasts Subscribe to DOC Updates, Diabetes Care "On Air", DiabetesBio, and The Points of CARE on Apple Podcasts, Amazon Music, Spotify, or your preferred platform.
July 24 · 34 min
Special Edition: Lp(a) & CV Risk
Over two decades ago, Lipoprotein(a)—or Lp(a)—was recognized as an emerging risk factor for cardiovascular disease. In this special edition of DOC Updates, Dr. Neil Skolnik explores our growing understanding of this cholesterol-carrying lipoprotein. This special episode is sponsored with support from Lilly. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. EPISODE NOTES Special Edition: Special Edition: Lp(a) & CV Risk In this special edition of DOC Updates, Neil Skolnik speaks with Dr. Michael Wilkinson, who goes over the history of Lp(a), the current guidelines, and the importance of screening. This special episode is sponsored with support from Lilly. Presented by: -Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health -Michael Wilkinson, MD, Associate Professor of Medicine at University of California San Diego Health, and Director of the advanced lipid treatment program at UC San Diego Health, Board of Directors of the National Lipid Association and Associate editor of the American Journal of Preventive Cardiology References: -The American Heart Association PREVENT Online Calculator -Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects – Circulation 2025; 151:400-415 -2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation Volume 153, Issue 17, 28 April 2026; Pages e1154-e1276
July 17 · 25 min
Special Edition: What's Next—Once-Weekly Insulins—Mechanisms and Practical Considerations
Continuing his exploration of once-weekly insulins, Neil Skolnik speaks with Aaron King, MD. Together, they cover the mechanisms, practical considerations, and the myriad benefits that this new therapy can have over daily basal insulin. This special episode is sponsored with support from Novo. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Aaron King, MD. Trained in the United States Navy in Family Medicine and certified by the American College of Diabetology, Dr. King practices outpatient diabetes management in San Antonio, Texas. Selected references: Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med 2023;389:297-308 Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. N Engl J Med 2025;393:325-335
July 7 · 28 min
Special Edition: What's Next—CKD in Type 1 Diabetes—An Urgent Need for Therapies
There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available for people with type 1. In this special episode, Dr. Neil Skolnik speaks with Janet McGill, MD, MA, FACE, FACP about the underdiscussed prevalence of CKD in type 1 and the importance of continued development in this area. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Janet B. McGill, MD, MA, FACE, FACP, Professor of Medicine at the University of Washington's John T. Milliken Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research Selected References: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121
June 30 · 34 min
Efficacy and safety of CagriSema & Retatrutide, CGM benefits beyond T2D, & more!
Welcome to the latest episode (July 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9 Bajaj H, Welch M, Shah P et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0 Melville, N. "CGM Monitoring Benefits Extend to Non-Insulin-Using T2D." Medscape, June 07, 2026 Aronne, L.J., Horn, D.B., le Roux, C.W. et al. "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial." Nat Med(2026) doi: 10.1038/s41591-026-04386-7 Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. doi:10.1001/jama.2026.8492 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.
June 25 · 25 min
Special Edition: Medications in the Pipeline for Cardiometabolic Disease
In this special edition of DOC Updates, Neil Skolnik speaks with Dr. Juan Frias, who catalogues the latest cardiometabolic medications, emphasizing the distinguishing characteristics of each. This special episode is sponsored with support from Lilly. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Juan Pablo Frias, MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science
S1 · E4
June 24 · 29 min
Special Edition: The Diabetes, Obesity, and CardioMetabolic CARE Symposium—The Cost of Obesity and Its Treatment
In this special episode of The Points of CARE, recorded live during the American Diabetes Association's (ADA) 2026 Scientific Sessions in New Orleans, hosts Richard Beaser, MD and Jane Reusch, MD highlight a new symposium on the clinical, social, and economic costs of treating—or not treating—individuals with obesity. This panel discussion is moderated by Louis J. Aronne, MD, Sanford I. Weill Professor of Metabolic Research at Weill-Cornell Medical College in New York, former president of the Obesity Society, and chair emeritus of the American Board of Obesity Medicine. Presenters: Timothy Dall, MS Managing Director for Life Sciences Consulting at GlobalData Melanie R. Jay, MD, Professor of Medicine and Population Health at the New York University Grossman School of Medicine Catherine Ferguson, MA, Vice President of Federal Advocacy for the ADA Featured Articles: The Cost of Inaction in Treating Obesity in the U.S. doi.org/10.2337/doci25-0011 Benefits and Costs of Treating Obesity Among Adults in Commercial Insurance Plans doi.org/10.2337/doci25-0006 Estimating the Health, Economic, and Social Benefits of Obesity Treatment Using Microsimulation Modeling doi.org/10.2337/doci25-0004 For more on the Cost of Obesity collection, visit diabetesjournals.org/collection/26413/Cost-of-Obesity To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.
S1 · E3
June 10 · 38 min
Anna Kahkoska & Joshua Niznik on Patient Portal Messages and Older Adults with T2D, Esben Thyssen Vestergaard on Clinic for Athletes with T1D, and more!
With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. 4:05 Our hosts speak with Anna Kahkoska, MD, PhD, Joan Heckler Gillings Assistant Professor in the Department of Nutrition and adjunct assistant professor of medicine in the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill, as well as Joshua Niznik, PharmD, PhD, assistant professor in the Division of Geriatric Medicine within the UNC School of Medicine. Their article, "Qualitative Analysis of Patient Portal Messages From Older Adults With Type 2 Diabetes," is available at doi.org/10.2337/doc25-0079. 14:10 Our hosts introduce Esben Thyssen Vestergaard, PhD, clinical associate professor in the Department of Clinical Medicine and Department of Pediatrics Aarhus University in Aarhus, Denmark. His article, "Clinic for Athletes With Type 1 Diabetes: Evaluation of a Structured Clinical Care Model for Physically Active Individuals," is available for free at doi.org/10.2337/doc25-0064. 21:40 Finally, Richard and Jane highlight some of their favorite articles from the May-June issue. Rezaeiahari, et al. Rural–Urban Differences in Use of Diabetes Self-Management Education and Support in Arkansas, 2015–2019 doi.org/10.2337/doc25-0065 Liu, et al. Trends in Nutrient Intake Among U.S. Adults by Diabetes Status: National Health and Nutrition Examination Survey 2011–2020 doi.org/10.2337/doc25-0076 Yanez Bello, et al. Barriers to the Adoption of Diabetes Technologies and the Implementation of Connected Insulin Pens in a Largely Minority Population With Type 1 Diabetes doi.org/10.2337/doc25-0072 Shehab, et al. Barriers to Effective Type 2 Diabetes Care in a Conflict-Affected Region of Syria: A Qualitative Study of Health Care Provider Perspectives doi.org/10.2337/doc26-0021 ElSayed, et al. Enhancing Physician Clinical Competency: A Cluster Randomized Trial of a Multimodal Online Educational Program in a Multinational Diabetes Workforce doi.org/10.2337/doci25-0007 Olesen, et al. A Danish Nationwide Cohort of Foot Health in Individuals With Diabetes From the Danish Foot Status Database doi.org/10.2337/doc26-0002 To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.
June 2 · 38 min
Food coloring additives & T2D, automated insulin delivery systems in T2D, and more!
Welcome to the latest episode (June 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Update: Shah S, et al. "Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort Diabetes Care. 2026;49(6):1067–1077. doi.org/10.2337/dc25-2727 Hespanhol L, et al. "Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis." Diabetes Care. 2026;49(6):1134–1143. doi.org/10.2337/dc25-2435 Tatum K, et al. "Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer." JAMA. Published Online: May 11, 2026 2026;9;(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133 Winkler C, et al. "Screening Children for Early-Stage Type 1 Diabetes." JAMA. Published Online: May 21, 2026 doi:10.1001/jama.2026.6085 Würtz Yazdanfard P, Kosjerina V, Wood-Kurland H et al. "Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024)" Lancet. Volume 66, 101716, July 2026. doi:10.1016/j.lanepe.2026.101716 Horn D, Aronne L, Wharton S et al. "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial." Lancet. Published online May 12, 2026. doi:10.1016/S0140-6736(26)00656-2 Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.
May 29 · 30 min
Special Edition: Obesity Processes and PATHWEIGH for Obesity Care
In this special edition of Diabetes Core Update, Neil Skolnik discusses PATHWEIGH, a novel obesity care process for primary care clinicians which has demonstrated a decrease in population weight gain. This special episode is sponsored with support from Lilly. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Leigh Perreault, MD, Professor of Pedicine in the Division of Endocrinology, Metabolism and Diabetes, at the University of Colorado Denver School of Medicine, Aurora, CO Reference: Perreault, L., Pan, Q., Rodriguez, C. et al. Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial. Nat Med 32, 645–652 (2026).
May 26 · 33 min
Special Edition: Obesity—The Changing Landscape
In the first episode of this series on Obesity, our host is joined by Dr. Mikhail Kosiborod to discuss the evolving science and cardiometabolic diseases associated with obesity. This special episode is sponsored with support from AstraZeneca. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Mikhail Kosiborod, MD, Senior Vice President Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca. Selected references: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation October 2023
May 19 · 27 min
Special Edition: What's Next—Cortisol, Metabolism & Future Innovation, Part 4
Is hypercortisolism the hidden culprit in a significant proportion of both difficult-to-treat diabetes and resistant hypertension? In part 4 of our special series, Dr. Neil Skolnik speaks with John Buse, MD to explore the effects of hypercortisolism, until just recently considered a vanishingly rare condition. This special episode is sponsored with support from Corcept. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John Buse, MD, The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award Selected references: Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care April 2025 Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care June 2025 MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension. HCP Live March 2026
May 12 · 30 min
Special Edition: What's Next—Cardiovascular Risk in CKD—The Overlooked Burden
We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these newly-discovered links between cardiovascular risk and CKD. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Josephine Harrington, M.D., Assistant Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine. Selected references: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121
May 5 · 20 min
Special Edition: What's Next—Once-Weekly Insulin
In the early 2000s, long-acting, once-daily insulin was approved, completely changing the experience of using insulin for people with diabetes. But science doesn't stand still. Now the FDA has approved weekly insulin. In this special episode of Diabetes Core Update, Neil Skolnik speaks with Athena Philis-Tsimikas, MD about this exciting development. This special edition of Diabetes Core Update is sponsored with support from Lilly. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Athena Philis-Tsimikas, MD, Corporate Vice President of the Scripps Whittier Diabetes Institute and Diabetes Care Line at Scripps Health in San Diego, CA
May 1 · 36 min
Associations between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy, Tirzepetide vs. Dulaglutide or Semaglutide on major cardiovascular events in T2D, and more!
Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month, they discuss: Marston NA, Bohula EA, Bhatia AK, et al. "Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277 Lee YJ, Lee SJ, Kim JW, et al. "Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283 Nissen SE, Wolski K, D'Alessio D, et al. "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767 Moura FA, et al. "Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238 Ostrominski JW, Ortega-Montiel J, et al. "Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063 Nicole Napoli, "Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

Showing 1–20 of 22 episodes